# A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

> **NCT00000884** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 84 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- **BIOLOGICAL:** ALVAC-HIV MN120TMG (vCP205)
- **BIOLOGICAL:** ALVAC-RG Rabies Glycoprotein (vCP65)

## Key facts

- **NCT ID:** NCT00000884
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2000-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000884, "A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*